What if we could use gene editing to treat Duchenne Muscular Dystrophy—not just manage symptoms, but address the underlying genetic cause in a scalable, precise way?
In this episode, Dr. Courtney Young, CEO of MyoGene Bio, shares how her company is using CRISPR technology to transform the treatment landscape for Duchenne Muscular Dystrophy, offering hope to patients and families facing this devastating disease.
What we discuss:
• The vision behind MyoGene Bio and why Duchenne Muscular Dystrophy
• How CRISPR gene editing works and why it's uniquely suited for Duchenne
• Scalability, precision, and safety considerations in gene editing therapies
• Navigating the regulatory pathway for CRISPR-based treatments
• Fundraising in the gene editing space and building investor confidence
• Leadership and culture: building a mission-driven biotech company
• Personal reflections on the future of gene therapy and rare disease treatment
This isn't just about treating one disease. This is about proving what's possible when gene editing meets rare disease—and opening the door for countless others.
About the Guest: Dr. Courtney Young is CEO of MyoGene Bio, a gene therapy company developing CRISPR-based treatments for Duchenne Muscular Dystrophy.
About the Show: Innovating Tomorrow's Medicine features conversations with biotech leaders, researchers, and innovators who are transforming bold ideas into real-world impact in healthcare and life sciences.
🔗 Connect:
• MyoGene Bio: [https://www.myogenebio.com]
• Courtney Young: [https://www.linkedin.com/in/courtney-young-mgb]
• Host Jeff Trickett: [https://www.linkedin.com/in/jeff-trickett]
📧 Questions or guest suggestions? [jeffreytrickett@gmail.com]
#Biotech #CRISPR #GeneEditing #DuchenneMuscularDystrophy #RareDisease #GeneTherapy #PrecisionMedicine #Innovation